Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
<h4>Background</h4>The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial demonstrated that higher-risk patients with atrial fibrillation had lower rates of stroke or systemic embolism and a similar rate of major bleeding, on average, when treated with dabigatran 15...
Guardado en:
Autores principales: | Samuel W Reinhardt, Nihar R Desai, Yuanyuan Tang, Philip G Jones, Jeremy Ader, John A Spertus |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe37bac7878e414e9a49ed71187a4699 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
por: Joyce H S You, et al.
Publicado: (2012) -
Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
por: Edrich T, et al.
Publicado: (2015) -
Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Clara Bonanad, et al.
Publicado: (2021) -
Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Dong Lin, et al.
Publicado: (2021) -
Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
por: Mikko Pyykönen, et al.
Publicado: (2021)